Skip to content
Assyro AI
Purple Book reference family · 351(a) biologic

belimumab (Benlysta)

belimumab is an FDA-licensed reference biologic from GlaxoSmithKline LLC.

351(a) biologicBLA 125370 GlaxoSmithKline LLC
Biosimilars
0
Interchangeables
0
Listed patents
0
Reference approved
2011

Reference product

Originator biologic
Ask AI
351(a)BLA 125370

Benlysta belimumab

GlaxoSmithKline LLC

View full reference-product record
Approved
Marketing
Rx
Center
CDER
Patents
None listed

Molecular structure

RCSB Protein Data Bank

Experimental 3D structure for belimumab from the RCSB Protein Data Bank (PDB 5Y9K).

3D molecular structure of belimumab (PDB entry 5Y9K)

Interactive biological assembly from PDB entry 5Y9K. Drag to rotate, scroll to zoom, and inspect the full atomic structure right here, with no need to leave the page.

Exclusivity & patent cliffs

Protection horizon
Ask AI
  1. Reference approval

    Approval date of the reference belimumab product.

    15 yr 11 mo ago

belimumab: frequently asked questions

Reference exclusivity, biosimilars, interchangeability, and patents for this molecule, from the FDA Purple Book.

Built from official FDA Purple Book records (monthly downloads, the Advanced Search interface, and the published Patent List), with reference-product, license-type, and exclusivity context for belimumab.

Related FDA reference tools

Assyro Intelligence

Ask anything about belimumab

Cited answers from FDA, EMA, Health Canada, PubMed and ClinicalTrials.gov, in seconds. Free, no sign-up.

  • PubMed
  • ClinicalTrials.gov
  • FDA
  • Health Canada
  • EMA
  • ICH

Evaluating for a team? Book a demo